MREO Overview
Upcoming Projects (MREO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MREO)
-
A Third Opinion: Discussing the current standard of care for Alpha-1 antitrypsin deficiency and the potential of Mereo BioPharma's alvelestat.
Ticker: MREO
Executed On: Dec 22, 2023 at 12:30 PM EST -
A Second Opinion: Discussing the current standard of care for Alpha-1 antitrypsin deficiency and the potential of Mereo BioPharma's alvelestat.
Ticker: MREO
Executed On: Dec 21, 2023 at 12:00 PM EST -
Discussing the current standard of care for Alpha-1 antitrypsin deficiency and the potential of Mereo BioPharma's alvelestat.
Ticker: MREO
Executed On: Dec 21, 2023 at 11:00 AM EST -
A look at the positive data from Mereo BioPharma's ongoing Phase 2/3 study of Setrusumab (UX143) in Osteogenesis Imperfecta
Tickers: MREO, RARE
Executed On: Jul 14, 2023 at 11:45 AM EDT -
A Second View: Discussing the recent Phase 2/3 data for Setrusumab currently in development to treat Osteogenesis Imperfecta in Pediatric and Young Adult patients
Tickers: MREO, RARE
Executed On: Nov 17, 2022 at 11:00 AM EST -
Discussing the recent Phase 2/3 data for Setrusumab currently in development to treat Osteogenesis Imperfecta in Pediatric and Young Adult patients
Tickers: MREO, RARE
Executed On: Oct 18, 2022 at 05:00 PM EDT
Upcoming & Overdue Catalysts (MREO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MREO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
